{"id":"W2770114427","doi":"10.1002/rth2.12053","title":"Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism","year":2017,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Idarucizumab; Medicine; Dabigatran; Anticoagulant; Adverse effect; Anesthesia; Clinical endpoint; Bolus (digestion); Randomized controlled trial; Clinical trial; Surgery; Internal medicine; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04210386,0.002320397,0.001890279,0.0007534688,0.001528982,0.002300581,0.002024488,0.004935798,0.01261052],"category_scores_gemma":[0.0234931,0.00130355,0.001785011,0.00058005,0.002937258,0.00185628,0.001220539,0.006604234,0.003730742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001596196,"about_ca_system_score_gemma":0.008795785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004045597,"about_ca_topic_score_gemma":0.000999228,"domain_scores_codex":[0.9769045,0.01787487,0.001147546,0.001412204,0.001774568,0.0008864021],"domain_scores_gemma":[0.9866023,0.004834614,0.002028964,0.0009544304,0.00167485,0.003904855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5096482,0.02229507,0.03037655,0.01351533,0.002240515,0.001012205,0.001235922,0.005350965,0.02101852,0.06229048,0.05093743,0.2800788],"study_design_scores_gemma":[0.5629771,0.1655087,0.01996629,0.007093405,0.002422659,0.0009055116,0.0003984975,0.009368398,0.009079116,0.0338981,0.1880828,0.000299399],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.05261223,0.008141392,0.05290412,0.02530982,0.004777666,0.823801,0.004666798,0.0004539103,0.02733314],"genre_scores_gemma":[0.1614806,0.002908921,0.1053333,0.02477821,0.001968482,0.6963199,0.001418217,0.00005437449,0.005737951],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.04210386,"threshold_uncertainty_score":0.2226691,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2340246830384615,"score_gpt":0.4694035610727331,"score_spread":0.2353788780342716,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}